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2Abstract
The mechanisms underlying the transition of rheumatoid arthritis (RA) systemic 
autoimmunity to the joints remain largely unknown. Here, we demonstrate that macrophages 
in the secondary lymphoid organs (SLOs) and synovial ectopic lymphoid-like structures 
(ELSs) express peptidylarginine deiminase 4 (PAD4) in murine collagen induced arthritis 
(CIA) and synovial biopsies from RA patients. Moreover, peptidyl citrulline colocalized with 
macrophages in SLOs and ELSs, and depletion of macrophages in CIA decreased lymphoid 
tissue citrullination and serum anti-citrullinated protein/peptide antibody (ACPA) levels. 
Furthermore, PAD was released from activated murine and RA synovial tissue and fluid (SF) 
macrophages which functionally deiminated extracellular proteins/peptides in vitro. 
Additionally, activated murine and SF macrophages displayed macrophage extracellular trap 
formation (METosis) and release of intracellular citrullinated histones. Moreover, 
presentation of citrullinated proteins induced ACPA production in vitro. Thus, lymphoid 
tissue macrophages contribute to self-antigen citrullination and ACPA production, indicating 
that their selective targeting would potentially ameliorate citrullination-dependent 
autoimmune disorders. 
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41. Introduction
Citrullination of various human proteins during the pre-clinical phase of rheumatoid arthritis 
(RA) is critical to breach of tolerance to self-antigens whose immune recognition may cross-
react with joint antigens to initiate the disease [1, 2]. The pre-clinical phase of RA may last 
years during which humoral and cellular factors, including macrophages [3] contribute to the 
generation of citrullinated antigens and induction of anti-citrullinated protein/peptide 
antibodies (ACPA) in secondary lymphoid organs (SLOs). In fact, compelling evidences 
supporting the role of SLOs in the generation and perpetuation of arthritogenic autoimmunity 
have emerged. In parallel with the appearance of serum auto-antibodies (-Abs), antigen-specific 
B and plasma cells localize within germinal centres (GCs) and medullary cords of peripheral 
reactive lymph nodes (LNs), and IgM rheumatoid factor (RF) is detectable in the LNs of 100% 
of seropositive patients but not in normal controls [4, 5]. Moreover, the autoimmune response in 
experimental arthritis was shown to start specifically in the LNs draining target joints, spreading 
thereafter to other lymphoid stations including the spleen [6]. However, the mechanism(s) 
mediating selective localisation of the disease to the joints, and the cells contributing to synovial 
membrane homing have not been fully decoded. As the disease progresses, ectopic lymphoid-
like structures (ELS) with active GCs develop in a large proportion of RA synovia [7-9] and the 
joints of mice with collagen-induced arthritis (CIA) providing plausible explanation for 
systemic-to-local transmission of the disease [10]. 
Citrullination corresponds to the conversion of arginine to citrulline by peptidylarginine 
deiminases (PADs). Five highly related calcium-dependent PADs have been described, and 
PAD4 is primarily expressed in the cells of the immune system and localizes to the cytoplasm 
and the nucleus [11, 12]. PAD2 and PAD4 are expressed in the synovial tissue of patients with 
RA and other arthritides, and inflammatory cells are a major source of PADs although PAD4 
also comes from hyperplastic synoviocytes [13]. A pathogenic role of PAD4 in autoimmune 
5arthritis has been illustrated in studies showing that PAD4 knockout mice develop less severe 
arthritis [14] and that global inhibition of PAD4 ameliorates CIA [15]. 
Systemic and local ACPA production has been related to SLOs and chronically inflamed 
synovia with ELS respectively [16]. At the synovial level, recent studies from out laboratory 
illustrated the production of ACPA recognising citrullinated histones contained in neutrophil 
extracellular traps (NETs)[17]. However, while neutrophils are scarce in RA synovial 
membranes, resident macrophages are abundant, they are topographically in proximity of ELS 
and can function as antigen presenting cells. This prompted us to hypothesise that macrophages 
associated with SLO and ELS express PAD and contribute to antigen citrullination and drive 
autoimmunity in arthritis. 
Using SLOs from CIA mice and synovial biopsies with ELSs from RA patients, we provide 
evidences that macrophages secrete functional PAD4 which deiminates extracellular antigens, 
colocalize with lymphoid tissue peptidyl citrulline and release citrullinated histones by 
macrophage extra cellular trap formation (METosis). We also show that presentation of 
citrullinated proteins by follicular dendritic cells (FDCs) to B cells induces ACPA production 
in germinal centre reactions (GCRs) in a T cell dependent manner.  Thus, our results support a 
novel role for macrophages in citrullinating proteins and driving autoantibody production via 
an FDC/T-cell dependent pathway both in SLO and ELS in the rheumatoid synovia, providing 
a mechanism for establishing and maintaining the disease in the joint.

62. Materials and Methods
2.1. Mice and collagen induced arthritis (CIA)
DBA/1 mice (males, 8-12 weeks of age) were purchased from Harlan Envigo, UK, and 
housed in the Biological Service Unit (BSU) at William Harvey Institute – Charterhouse 
Square – London – UK. To induce CIA, mice were sensitized to bovine collagen type II 
(MDBioscience, 804001) in Freund’s complete adjuvant, and synchronized with a boost of 
collagen in incomplete adjuvant on day 21. Mice were lightly anesthetized with isoflurane. 
The base of the tail was shaved and 100 μl collagen II/FCA emulsion (0.1 mg M.tb., H37RA, 
Difco, 231141/100 μL Freund’s incomplete adjuvant, Sigma F5506; Final concentration 
200 μg collagen II/100 μL FIA) was injected intradermally to the left-hand side of this site. 
21 days after initial sensitization, collagen II was dissolved in acetic acid as above, emulsified 
in Freund’s incomplete adjuvant and 100 μL (200 g collagen II) injected into the base of the 
tail on the right-hand side of the tail base. Mice were individually marked and assessed by 
blind observation three times a week for the development of arthritis and the clinical arthritis 
scores were recorded. Every inflamed main digit scored one, inflammation of the front paw 
scored one, inflammation of the hind paw scored one, and involvement of the ankle scored 
one. Thus, a maximal score for each animal was 22, and results were expressed as the total 
arthritis score of the group (6-8 mice / group). All experimental procedures were approved by 
the UK Home Office (project license PIL 70/23296). 
2.2. RA synovial tissues and histological grading  
Synovial tissues were obtained by ultrasound-guided synovial biopsy from DMARD-naïve 
patients with early (<12 months) RA (n=99), enrolled in the Pathobiology of Early Arthritis 
Cohort (PEAC) cohort (http://www.peac-mrc.mds.qmul.ac.uk) of the Centre for Experimental 
Medicine and Rheumatology of Queen Mary University of London as previously described 
7[18]. All patients fulfilled the 2010 EULAR criteria for RA [19]. Patients had clinically 
defined synovitis but duration of symptoms of less than 12 months and were all naïve to 
DMARD and steroid therapy. Upon enrollment, patients underwent ultrasound-guided 
synovial biopsy of a clinically active joint [18]. All procedures were performed following 
written informed consent and were approved by the hospital’s ethics committee (REC 
05/Q0703/198). Synovitis was semi-quantitatively assessed (0-9) according to a previously 
validated score (Krenn) [20]. Sequentially cut sections were stained with anti CD20cy (L26), 
CD3 (F7.2.38), CD68 (KP1), and CD138 (MI15) all from DAKO and each slide underwent 
SQ scoring (0-4), as previously reported [7]. Synovial pathotypes were defined as i) 
Lymphoid (L) CD20≥2 and/or CD138>2;  ii) Myeloid (M) CD68SL≥2, CD20≤1 and/or 
CD3≥1, CD138≤2; and iii) Fibroid (F) CD68SL<2 and CD3, CD20, CD138<1 
2.3. Immunohistochemistry and confocal imaging
SLOs (spleens and LNs) from CIA mice and synovial tissues with ELSs from RA patients 
were embedded in O.C.T (Sakura) and 10 µm cryo-sections were cut and fixed in ice cold 
acetone. The slides were rehydrated/Blocked with 2% horse serum (Jackson 
ImmunoResearch, 008-000-121) in PBS at room temperature in a humidified chamber, then 
incubated at room temperature with primary Abs for 2 hrs followed by 3x wash in PBS then 
incubation with secondary Abs for 1 hr. After incubation with the secondary Abs, the slides 
were washed in PBS 3 times, dried and mounted with Vectashield Antifade Mounting 
Medium (Vector Laboratories), cover-slipped, and examined with a Leica TCS SP2 AOBS 
confocal laser-scanning microscope. Three lasers (488, 543, and 633 nm) were used and far 
red emission is shown as pseudo-colour. Parameters were adjusted to scan at 1024 x 1024-
pixel density and 8-bit pixel depth. Emissions were recorded in three separate channels, and 
digital images were captured and processed with Leica Confocal Software LCS Lite. The Abs 
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8used in this study are listed in the table 1 and their concentrations ranged between 5 and 10 
g/ml.
2.4. Measurement of tissue citrulline 
The citrulline content in mice spleens was measured using the quantitative sandwich ELISA 
Mouse Citrulline (CIT) ELISA kit (Cat#MBS027373, MyBioSource, San Diego, CA) 
according to the manufacture instructions and data was expressed as the optical density (O.D.) 
read at 450 nm. 
2.5. Macrophage depletion 
Macrophages were depleted in DBA/1 mice by i.p injection of 250 g / mouse F4/80 mAb for 
three successive days before CIA induction. The F4/80 ATCC® HB-198™ hybridoma was 
used for the generation of sufficient amounts of the mAb F4/80 that was purified from the 
culture supernatants on protein G columns in the protein purification facility at Queen Mary 
University of London. The efficacy of depletion was assessed before CIA induction using 
multicolour flow cytometry of single cell suspensions prepared from the spleens and LNs. 
After Fc blockade with TruStainFcX (Biolegend, 101320), a panel of CD19 PE (Biolegend, 
115508), CD3 AF488 (Biolegend, 100321), CD11b BV605 (Biolegend, , 101257) and F4/80 
PE-Cy7 (Biolegend, 123114) was used and the plots were gated on the non B / non T cells. 
The % of F4/80+ cells in treated and untreated mice groups was calculated.
2.6. Murine FDC, B cell, and T cell isolation
FDCs were isolated by positive selection from normal DBA/1 mice spleens and LNs as 
recently described [21]. Briefly, single cell suspensions were prepared from the tissues then 
sequentially incubated with FDC-specific Ab (FDC-M1, BD Biosciences, 551320) for 45 
min, 1 μg of biotinylated anti-rat κ L chain (BD Biosciences, 553028) for 45 min, and 20 μl of 
anti-biotin microbeads (Miltenyi Biotec, 130-090-485) for 15–20 min on ice. The cells were 

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9layered on a MACS LS column (Miltenyi Biotec, 130-041-306) and washed with 10 ml of 
ice-cold MACS buffer. The column was removed from the VarioMACS, and the bound FDCs 
were released with 5 ml of MACS buffer. B220+ B cells were isolated from CIA mice using 
CD45R (B220) MicroBeads from Miltenyi Biotec (130-049-501), and T cells were purified 
using the Pan T Cell Isolation Kit II, mouse (Miltenyi Biotec, 130-095-130). 
2.7. Macrophage isolation and in vitro activation
Murine macrophages were purified using EasySep Mouse CD11b Positive Selection Kit II 
(STEMCELL Technologies, 18770). Macrophages were tagged with CD11b Abs and 
magnetic particles, then isolated using an EasySep magnet. A stock solution of 1mg/ml LPS 
(InvivoGen, UK, tlrl-eklps) was prepared using endotoxin-free water and 1x106 purified 
macrophages were stimulated with 10, 100, and 1000 ng/ml LPS in 400 ul DMEM for 4 hours 
in 8-well culture slides. Unstimulated and PMA -stimulated (1 g/ml) cells were used as 
negative and positive controls respectively. PMA was burchased from SigmaAldrich (P8139). 
Culture supernatants were collected and assessed for PAD release by ELISA, and attached 
macrophages were stained with nuclear stain and anti-citrullinated histones to visualize 
METosis by confocal microscopy.
2.8. Activation and visualization of METosis in synovial fluid (SF) macrophages 
SF samples were obtained from inflamed knees of ACPA+ patients in sterile Na Heparin 
vacutainers and the cells were collected by centrifugation at 2,000 rpm for 10 minutes. 
PMNLs and mononuclear cells were isolated by double density gradient centrifugation using 
Histopaque 1119 (SigmaAldrich, 11191) and Histopaque 1077 (SigmaAldrich, 1077). The 
mononuclear cells were harvested, counted and macrophages were enriched by attachment 
then stimulated with LPS as described in the murine macrophages. Unstimulated human 
tonsillar macrophages were included as a control, culture supernatants were collected after 24 

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hrs, and PAD activity was assessed in the supernatants on fibrinogen coated ELISA plates. 
Slide preparations of SF macrophages were Giemsa stained and visualized by light 
microscopy. Nuclei, PAD4 and citrullinated histones were also stained and assessed by 
confocal microscopy. 
2.9. Synovial organ cultures 
RA synovial biopsies were cut into small homogenous pieces (i.e. 20-40mg) avoiding fat and 
connective tissue. The synovial pieces were gently transferred into cell culture inserts 
(Millicell, PIHA01250) mounted in 24-well plates containing 600 ul RPMI with 10% FCS. A 
drop of medium was added on top of the tissues and the plates were incubated for 24h at 
37°C. After 24 hrs, 300 µl from each well were collected and replaced with 300µl medium for 
further 24 hrs then culture supernatants were collected and synovial tissue lysates were 
prepared. 
2.10. In situ citrullination of fibrinogen 
The ability of the released PAD in the culture supernatants of RA SF macrophages and organ 
cultures to citrullinate extracellular antigens was assessed by in situ citrullination of native 
human fibrinogen (SigmaAldrich, F3879). To generate a standard curve, human fibrinogen 
was first citrullinated using rabbit skeletal muscle PAD (SigmaAldrich, P1584) (7 U/mg 
fibrinogen) and used for ELISA coating starting with 0.5 g/mL with 1:2 serial dilution. 
Samples were incubated on native fibrinogen-coated wells (250 ng/ml) for 4 hours at 37OC 
and CaCl+2 in the reaction mixture was adjusted to 10mM. Generation of citrulluinated 
fibrinogen due to PAD activity was then assessed using human anti-citrullinated fibrinogen 
mAb (ModiQuest, clone 1F11 CAT No. MQR 2.101-100) that specifically binds deiminated 
but not native fibrinogen. The human mAb was detected using HRP-conjugated goat anti 
human IgG secondary (Thermofisher Scientific, 62-8420) HRP was developed using TBM 

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(Vectorlabs, SK-4400), and ODs at 450 nm were read using multiwall plate reader (BMG 
LABTECH, UK) and MARS data analysis software.  
2.11. PAD activity ELISA assay
PAD activity in the undiluted culture supernatants of activated murine macrophages was 
assessed using Ab Based Assay for PAD activity (ABAP) (ModiQUEST, MQ17.101-96) 
following the manufacturer instructions. Principally, after incubation of the culture 
supernatants on plates pre-coated with arginine-containing peptides, an HRP-labelled 
monoclonal mAb is used to detect deiminated arginine (citrulline) and the ODs measured at 
450 nm after development of the TBM substrate are calculated. 
2.12. Immune complex (IC) preparation and in vitro GCRs
CIA sera react with citrullinated but not native human fibrinogen [22]. Citrullinated 
fibrinogen ICs were generated by incubating 100 ng citrullinated human fibrinogen with 100 
ul serum taken from CIA mice with anti-cyclic citrullinated peptides (CCP) > 50 U/ml for 1 h 
at 37°C. The ICs were loaded on FDCs for 1 hr at 37OC then the cells were washed in PBS 
and retention was confirmed by IF using rabbit anti-human fibrinogen Ab followed by 
rhodamine-conjugated anti rabbit secondary. FDCs were then co-cultured with B and T cells 
purified from the CIA spleens where 1x106 B cells/culture were used at a ratio of 1 FDC : 2 B 
cells : 1 T cell. In vitro cultures were maintained for 5 days, then undiluted culture 
supernatants were assessed for anti-CCP IgG production using ELISA.
2.13. In vitro generation of Tingible Body Macrophages (TBM)
Purified murine B cells were labelled with CSFE using the CellTrace™ CFSE Cell 
Proliferation Kit (ThermoFisher, C34554) then incubated with anti-mouse CD95 (Fas) Ab 
(Biolegend, 152803 )(0.25/ g/106 cells) at 37°C for 3 hours to induce B cell apoptosis. 
Apoptotic B cells were then incubated with splenic macrophages enriched by attachment for 3 

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hours to allow uptake and TBM generation. TBMs were stimulated with 10 ng/ml LPS for 4 
hours in slide cultures then stained with anti CD68 and nuclear stain and METosis of TBMs 
was assessed by confocal microscopy.    
2.14. Measurement of anti-CCP levels 
Axis-Shield anti-CCP ELISA kit (Axis-Shield Diagnostics Ltd, FCCP600) was used 
according to the manufacturer instructions with modifications to assess mouse anti-CCPs. The 
secondary anti human Ab provided in the kit was replaced with an anti-mouse HRP 
conjugated secondary (AffiniPure Goat Anti-Mouse IgG (H+L) (Jackson ImmunoResearch 
115-035-003 diluted 1:5000). Sera were used at 1:10 dilution; and culture supernatants were 
assessed undiluted with data calculated after subtraction of potential backgrounds due to Abs 
in the ICs. The cut-off for the sera followed a previous report applying  a similar protocol and 
using sera from Rag1–/– and unimmunized DBA/1 mice [22]. The cut-off for culture 
supernatants was calculated as 3 standard deviations above the mean value of unstimulated B 
cell cultures from unimmunized DBA/1 mice.
 Preparation of tissue and cell lysates and immunoblotting
Murine tissue and cell lysates from the skin, spleens, LNs, and purified macrophages were 
prepared by homogenization in Ripa buffer and 1% protease inhibitor cocktail. Protein 
concentrations were determined using BCA Protein assay and 25 g protein / sample were 
separated by SDS PAGE. Recombinant mouse PAD4 and GAPDH were used as controls, and 
MW markers were included. Proteins separated by SDS-PAGE were imaged by UV then 
transferred to nitrocellulose membranes and the immunoblots were incubated with mouse 
anti-PAD4 (Santa Cruz, sc-365369) diluted 1:500 followed by goat anti-mouse IgG-HRP 
(Santa Cruz, sc-2005) at 1:2000 dilution. Clarity Max Western ECL Substrates (Bio-rad, 

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1705061) was used for detection and membranes were exposed to Amersham films that were 
developed and fixed. 
2.15. RNA-Seq analysis 
CD68 and PADI4 expression were analysed using RNA-Seq data generated from RA synovial 
tissue and matched blood samples enrolled in the PEAC cohort. Transcript abundance was 
derived from FASTQ files over GENCODE v24/GRCh38 transcripts using Kallisto v0.43.0. 
Transcript abundances and average transcript lengths were imported into R using 
Bioconductor package tximport 1.4.0 and summarised over NCBI RefSeq transcript isoforms. 
Imported abundances were normalised in R, including a correction for average transcript 
length and incorporating batch, sex, and pathotype as model covariates, using DESeq2 1.14.1. 
Transcript abundances underwent regularised log expression (RLE) transformation and 
depicted on the Y axis whereas the synovial pathotypes were shown on the X axis. 
Differential expression analysis based on negative binomial distribution using regression 
models of normalised count data was performed using DESeq2 and a likelihood ratio test to 
compare variation between pathotype groups in the synovium followed by pairwise 
comparisons between Lymphoid, Myeloid and Fibroid groups. P values were converted to Q 
values based on Benjamini-Hochberg false discovery rate (FDR), using FDR cut-off set at 
Q<0.05 to define differentially expressed genes. 
2.16. Mander’s colocalization coefficient 
In situ correlation of CD68, peptidyl citrulline, and PAD4 was analyzed using the Mander’s 
(R) overlap coefficient plugin in Image J. Before running the algorithm, backgrounds were 
subtracted, and thresholds were automatically assigned. Correlation plots were generated and 
coefficients calculated. Mander’s R colocalization ranges between 0 = no localization, and 1 = 
maximum colocalization.       
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2.17. Statistical analysis
Significant differences were calculated with GraphPad using Student’s T test and p values of 
< 0.05 were considered statistically significant.
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3. Results
3.1. PAD4 is expressed in the secondary lymphoid tissues of CIA mice and colocalizes 
with CD68+ macrophages
In RA, ACPA production precedes the onset of clinical arthritis indicating a role of extra 
articular sites, peripheral and lymphoid, in autoantigen citrullination and autoAb production. 
Here, we sought to see if ACPA production similarly precedes arthritis in CIA mice; and 
evaluate the expression and source of the citrullination enzyme PAD4 at the peripheral site of 
antigen challenge, the skin, and the secondary lymphoid tissues draining this site. 
First, we induced CIA in male DBA/1 mice and assessed the total arthritis score and the anti-
CCP levels in the sera of these mice. Figure 1-A demonstrates that by day 21 anti-CCP Abs 
were detectable in the sera of CIA mice but not in unimmunized controls. While anti-CCP 
autoAbs were measurable in the sera of CIA mice at day 21, arthritis was not clinically 
detectable, and the total arthritis score was comparable with unimmunized controls (Figure 1-
B) indicating that anti-CCP Abs precedes clinical arthritis in CIA. The anti CCP levels were 
further measured on day 28 and at a terminal bleed on day 42 attaining levels of 30+9 (SEM) 
and 41+12 (SEM) respectively. Using unpaired 2-tailed student T test, the serum levels of anti 
CCP were significantly higher on day 42 (p = 0.047) but not  on day 28 (p = 0.25) when 
compared to day 21.
Induction of anti-CCP Abs requires citrullination of auto-antigens, and consequently we 
sought to determine whether the citrullination enzyme PAD4 is expressed at the site of 
antigen entry, the skin, and / or the inguinal and popliteal LNs draining the skin of the base of 
the tail of CIA mice. Western blotting (WB) of the skin and LN lysates from 3 different mice 
(Figure 1-C) showed that PAD4 immunosignal was detectable at the expected MW (~67 Kd) 
in the draining LNs but not in the skin lysates indicating that SLOs are sites of PAD4 

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expression where citrullinated proteins and peptides could be generated and presented. 
Furthermore, PAD4 was also expressed in other SLOs, the spleens, of CIA mice, as indicted 
by WB (Figure 1-D).
Neutrophil-PAD4 has been associated with the pathogenesis of autoimmune arthritis, 
however, neutrophils are not abundant in SLOs, prompting our investigation of the cellular 
source of PAD4 in these tissues. Our preliminary studies indicated that PAD4 is distributed in 
macrophage-rich areas of SLOs, suggestive of a macrophage source of this enzyme. To test 
this, we performed confocal imaging of immuno-labelled cryo-sections of CIA spleens and 
DLNs as shown in Figure 1-E, and 1-F. Dual and triple overlays of PAD4, CD68, and CD11c 
staining indicated that PAD4 maximally co-localizes with CD68+ macrophages in the spleen 
and LNs with less overlap with the dentritic cell marker CD11c. In fact, PAD4 followed the 
regional distribution of CD68 in the subcapsular sinus, the paracortical, and the medullary 
regions of the DLNs with relatively less expression in the B cell follicles in the cortex (Figure 
1-F). Furthermore, high magnification imaging of the DLN medullary regions (Figure 1-G) 
resolved intracellular expression of PAD4 in CD68+ macrophages. Moreover, PAD4 was 
detectable in the GC induced in the DLNs of the CIA mice and colocalized with CD68+ 
tingible body macrophages (TBMs) containing GL7+ fragments of GC B cells (Figure 1 H-J).  
To further confirm that SLT macrophages produce PAD4, lysates of CD11b-purified 
macrophages from the spleen and LNs were analysed by WB and the PAD4 immunosignal 
was detectable at the expected MW (~67 Kd) in lysates prepared from 3 different CIA mice 
(Figure 1-K). Overall, this supports that macrophages express PAD4 in SLOs of CIA mice 
where citrullinated proteins and peptides can be presented to induce ACPA production.   
3.2. Citrullinated proteins/peptides colocalize with CD68+ macrophages in the draining 
LNs and spleens; and macrophage depletion decreases lymphoid tissue citrulline 
and serum ACPA levels in CIA mice
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Having established the expression of PAD4 by macrophages in CIA SLOs, we then 
proceeded to investigate the distribution of citrullinated proteins/peptides in relation to the 
macrophages’ CD68 and assess the impact of macrophage depletion on SLOs citrulline 
content and serum anti-CCP levels. Our initial attempts (not shown) to label citrullinated 
proteins/peptides in SLOs were associated with high backgrounds due to Ab binding to both 
free and peptidyl citrulline. Since free citrulline is a member of the citric acid cycle and its 
metabolism is not regulated by peptidyl arginine deiminases (PADs) or associated with the 
pathogenesis of autoimmune arthritis, we used a mAb (anti-peptidyl citrulline, clone F95) 
that specifically binds peptidyl- and protein-bound citrulline but not the free form of 
citrulline. Figure 2-A illustrates the distribution of citrullinated peptides/proteins in the DLNs 
of CIA mice with overlays showing colocalization with CD68+ macrophages (Figure 2A i-ii). 
In the LN cortex (Figure 2A iii), peptidyl citrulline colocalized with the subcapsular sinus 
macrophages and displayed a dendritic pattern in the B cell follicles suggestive of retention 
on FDCs. This was later confirmed by colocalization with FDC-CD21 and the GC B cell 
marker GL7 (Figure 5). Similarly, citrullinated peptides/proteins colocalized with CD68+ 
macrophages in the spleen (Figure 2B i) and showed intrafollicular dendritic pattern 
suggestive of FDC association. 
The presence of citrullinated peptides/proteins in association with SLOs macrophages 
prompted us to investigate the impact of macrophage depletion on the citrulline content of 
these organs and if decreased citrulline is associated with lower serum anti-CCP levels. To 
test this, macrophages were depleted in DBA/1 mice by i.p. administration of the mAb F4/80 
for three successive days before induction of CIA and effective depletion was assessed by flow 
cytometry. As expected, F4/80 treatment reduced the F4/80+ cells in the different subsets of 
splenic macrophages (F4/80+ / CD11b-, F4/80+ / CD11blo, and F4/80+ / CD11bhi) compared to 
PBS treated controls (Figure 2C and D) with less effect on F4/80- macrophages. Moreover, 
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macrophage depletion by F4/80 was associated with significant reduction (p < 0.05) in the 
citrulline content of the CIA spleens 3 and 4 weeks after CIA induction (Figure 2E); which 
correlated with significant inhibition in serum anti-CCP levels (p < 0.05) compared to mAb-
untreated mice (Figure 2F). Macrophages repopulated lymphoid tissues in macrophage-depleted 
mice with comparable ratios in F4/80-treated and controls 3 weeks after collagen II 
administration as previously reported [23]. Collectively, this suggests that macrophages 
contribute to the generation of citrullinated proteins in SLOs and their depletion reduces the tissue 
citrulline content and the serum anti-CCP levels. 
3.3. Activated macrophages release PAD4 and exhibit extracellular trap formation 
(METosis) 
The preceding data suggest that macrophages contribute to the level of citrullinated antigens in 
SLOs which in turn influences the serum anti-CCP levels. Thus, we next sought to reveal 
potential mechanisms that may underly this contribution. Full differentiation of B cells into anti-
CCP-producing plasma cells requires co-signals from antigen-specific T cells which can be 
stimulated by macrophages as professional antigen presenting cells. However, T cell help is not 
the sole requirement for B cell activation, and effective engagement of the BCR with antigens in 
the extracellular space is essential for cognate recognition and antigen-specific B cell responses. 
Both extracellular (e.g. citrullinated fibrinogen), and intracellular (e.g. citrullinated histones) 
antigens are targeted by ACPAs in autoimmune arthritis; and we reasoned that macrophage 
activation contributes to the availability of both targets by PAD4 release and macrophage 
extracellular trap formation (METosis) respectively. A vast array of molecules can activate 
macrophages in the context of autoimmune arthritis, including but not limited to proinflammatory 
cytokines, TLR ligands, and ICs; and we used LPS as a classic macrophage activator. To test 
citrullination of extracellular antigens by released macrophage PAD4, we used commercial 
ELISA plates coated with arginine-containing peptides and detected conversion of arginine into 
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citrulline using specific anti-citrulline Ab. Figure 3A indicates that unstimulated murine splenic 
macrophages release PAD4 at baseline, and this release can be significantly induced by PMA 
(positive control) and different concentrations of LPS. To further investigate if activated 
macrophages can also contribute to the provision of citrullinated intracellular targets via METosis, 
murine splenic macrophages were stimulated with PMA and LPS and stained with nuclear and 
citrullinated histone stains. As shown in figure 2B, activated macrophages released intracellular 
citrullinated histones that were detectable in the extracellular space but not in unstimulated 
controls (Figure 3B). TBMs are unique subset of lymphoid tissue macrophages that promote 
peripheral tolerance by eliminating apoptotic B cells from the GCs. However, this critical role can 
be reversed if macrophage activation also induces METosis in TBMs when not only macrophage 
citrullinated proteins will be released in the vicinity of the GCs, but also their cargo of apoptotic B 
cell fragments will be made available to the hypermutating BCRs. To this end, we generated 
TBMs in vitro using CSFE-labelled apoptotic B cells and stimulated them with LPS and 
visualized the cells with confocal microscopy. As shown in figure 3C, apoptotic B cell fragments 
were released from TBMs in association with the DNA extra cellular traps. Altogether, these 
data suggest that activated macrophages contribute to the availability of extracellular and 
intracellular citrullinated antigens by releasing PAD and METosis respectively.
3.4. Anti-CCP Ab production is T cell dependent
The mere availability of citrullinated antigens would not effectively induce B cell activation, 
plasma cell differentiation, and anti-CCP production. GCs are the hotspots in lymphoid 
tissues where FDCs and primed Tfh cells provide antigenic and non-antigenic signals that 
efficiently activate B cells and induce class switching and high affinity Ab production. While 
FDCs present antigens to B cells as ICs in the GCs of the LN cortex, T cell priming mainly 
occurs in the deep cortical units (paracortex) which, following activation, migrate to the GCs, 
where they provide cognate help and ICOS/CD40L-mediated B cell co-stimulation. Together 
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with FDC-derived co-signals, Tfh cells induce CSR, SHM, affinity maturation and memory B 
cell generation. Here we asked if (1) peptidyl citrulline colocalizes with macrophages 
interacting with T cells in the paracortex, and FDCs interacting with GC B cells in the cortex; 
(2) activation of B cells with citrullinated fibrinogen loaded-FDCs requires T cells for anti-
CCP IgG production in in vitro GCRs. To answer these questions, we first used confocal 
imaging of the DLNs of CIA mice to delineate the association of peptidyl citrulline with 
FDCs and macrophages. Figure 4A illustrates the colocalization of peptidyl citrulline with 
CD68+ macrophages and CD3+ T cells in the paracortex where T cell priming occurs, while 
figure 4B shows peptidyl citrulline retention on the CD21+ FDC reticula where B cell 
activation by FDC-ICs is induced. In addition, well-developed GCs supported by peptidyl 
citrulline-retaining FDCs and ICOS+ Tfh cells (Figure 4C), were detectable in association 
with Blimp-1+ plasma cells (Figure 4D) in the secondary B cell follicles situated in the 
cortices of the draining LNs. We have previously demonstrated a novel T cell-independent 
pathway of B cell activation by multimerized antigens on FDCs [24, 25] where extensive 
crosslinking of the BCRs by FcRIIB-retained antigens in the presence of FDC-derived BAFF 
and C4bBP induced robust GCRs and antigen-specific Ab response. So, we sought to 
determine if a similar T independent pathway could mediate B cell activation and anti CCP 
autoAb production in autoimmune arthritis. To test this, we purified FDCs from normal 
DBA/1 mice spleens and loaded them with citrullinated fibrinogen ICs (Figure 4E), then, we 
set up in vitro GCRs (Figure 4F) using IC-loaded FDCs with  B and T cells purified from CIA 
spleens where the presence of citrullinated fibrinogen specific CD4 T cells has been 
previously substantiated [26]. Cultures were maintained for 5 days then anti-CCP IgG was 
measured by ELISA. As shown in figure 4G, anti-CCP IgG was induced only in the presence 
of T cells and citrullinated fibrinogen on FDCs but not in antigen- or T cell-deficient cultures. 
Collectively, the synergistic effect of Tfh-mediated B cell co-stimulation and the presentation 
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of citrullinated antigens by FDCs to B cells during the GCR are critical for induction of anti-
CCP IgG autoAbs.
3.5. Tissue macrophages expressing PAD4 colocalize with peptidyl citrulline, and 
correlate with ELSs in RA synovium
We next investigated whether results obtained in the murine CIA SLOs were operational in in 
RA synovial tissues. First, we assessed PAD4 expression and peptidyl citrulline distribution 
in the synovial membranes using IHC. Figure 5A indicates that PAD4 colocalizes with CD68+ 
macrophages in the inflamed synovia, however, its distribution is not restricted to 
macrophages. In fact, a strong PAD4 signal with serpentine pattern, suggestive of a vascular 
association, is detectable in the synovial tissues distinguishable from the CD68 macrophage 
marker. In addition, peptidyl citrulline colocalized with intimal and subintimal CD68+ 
macrophages in the RA synovium (Figure 5B). Furthermore, PAD4 expressing CD68+ 
macrophages were present within follicular structures mirroring TBMs of the GCs (Figure 
5C). To compare the relative distribution of peptidyl citrulline in relation to macrophages, T 
cells, FDCs, and B cells, we used adjacent sections from RA synovia with ELS and scanned 
them for different cellular components. As observed in the CIA SLOs, peptidyl citrulline 
colocalized with CD68+ macrophages interacting with CD3+ T cells (Figure 5D), retained on 
CD21+ FDCs (Figure 5E) in association with well-formed ELS (CD20hi, CD3+; figure 5F). 
Moreover, the plasma cell transcription factor Blimp-1 was detectable in these ELSs as shown 
in figure 5G. The association of CD68+ macrophages with the cellular architecture of ELSs in 
RA synovia was further confirmed by RNA-Seq expression analysis. Figure 5H shows that 
CD68 expression significantly correlate with the lymphoid and myeloid pathotypes compared 
to the fibroid synovial pathotypes (Lymphoid v Myeloid adjusted p 1.1e-01; Myeloid v 
Fibroid adjusted p 6.5e-02; Lymphoid v Fibroid adjusted p 3.6e-05). In addition, CD68 
expression is significantly higher in the lymphoid pathotype and strongly correlates with the 
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histological scoring of the T, B, and plasma cell markers CD3, CD20, and CD138 
respectively. Moreover, CD68 significantly correlates with the genes encoding CD3epsilon (T 
cell, also CD3gamma and CD3delta – data not shown), MS4A1 (B cell, CD20), CR2 (FDC, 
CD21), and PRDM1 (plasma cell, Blimp-1) (Figure 5I). We also calculated the co-
distribution of CD68, peptidyl citrulline, and PAD4 in the RA synovium using Mander’s 
colocalization algorithm where 0 indicates no colocalization and 1 indicates maximum 
colocalization. Mander’s correlation coefficients were 0.7+ 0.4, 0.76+0.6, 0.75+0.5 for 
CD68/peptidyl citrulline, PAD4/peptidyl citrulline, and CD68/PAD4 co-distribution 
respectively (Figure 5J i-vi]. While intracellular PAD4 colocalized with the macrophage 
marker CD68 (Figure 5J vii white box), and extracellular PAD4 (Figure 5J vii dashed white 
box) was seen in proximity to macrophages, again (as seen in Figure 5A), a distinct signature 
of PAD4, potentially associated with vessel walls but not with macrophages, was evident in 
the RA membranes (Figure 5J vii double white box). Thus, although SLOs are 
developmentally dictated while ELSs are inducible by inflammation, the expression of PAD4 
by macrophages, the retention of peptidyl citrulline on FDCs, and the interaction between the 
different cellular components display similar mechanisms.   
3.6. RA synovial fluid (SF) macrophages and synovial organ cultures release PAD 
and citrullinated histones and display METosis
 Given some similarities between SLOs and ELSs regarding PAD4 expression and peptidyl 
citrulline association with macrophages, we speculated that similar mechanisms of PAD 
release and METosis by RA macrophages could contribute to the provision of citrullinated 
extracellular and intracellular antigens respectively. To this end we separated macrophages 
from freshly aspirated SF using Ficoll followed by attachment then stimulation with LPS. 
Human tonsillar macrophages enriched by attachment were used as a control. In addition, 
ELS+ RA synovial tissue organ cultures (whole tissue – without macrophage purification) 
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were also tested.  As illustrated in figure 6A-i, PAD activity was significantly higher in 
freshly isolated SF macrophages culture supernatants compared to control tonsillar 
macrophages, and stimulation with LPS did not promote further activation. In addition, PAD 
was secreted in the culture supernatants of RA synovial organ cultures (figure 6B) as detected 
using in situ citrullination of native fibrinogen as a read out (figure 6B-i). We also stained 
freshly isolated SF macrophages to assess the presence of extracellular traps, release of 
PAD4, and citrullinated histones using light and confocal imaging. Figure 6A-ii shows 
extruded nuclear material outside a group of mononuclear cells, and the networks of extruded 
DNA (METosis) are associated with citrullinated histones and PAD4 as illustrated in 6A-iii, 
and 6A-iv respectively. These results suggest that PAD secretion by activated RA SF and RA 
tissue macrophages contributes to citrullination of extracellular antigens (native fibrinogen in 
this assay), and that METosis provides a mechanism for the release of intracellular 
citrullinated antigens including histones.        
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4. Discussion
SLOs and synovial ELSs are sites of autoAb production in autoimmune arthritis [5, 8, 27]. 
Herein we investigated the hypothesis that macrophages at these sites play a major role in 
protein citrullination and ACPA production. We demonstrated that in SLOs from CIA mice 
and ELSs from RA synovial biopsies macrophages express PAD4, co-localize with peptidyl 
citrulline and their activation results in PAD release and METosis. Furthermore, macrophage 
depletion in CIA decreases tissue citrulline and serum ACPA levels, whereas, presentation of 
peptidyl citrulline by FDCs to B cells induces T-cell dependent ACPA production.
The emergence of anti-CCP Abs prior to clinical manifestations is a hallmark of human and 
experimental autoimmune arthritis as confirmed in this study and reported earlier in CIA 
DBA/1 mice [22]. In RA, these autoAbs are detectable in the patients’ sera >10 years before 
the onset of articular manifestations [28]; however, the mechanisms by which such systemic 
autoimmunity localizes to the affected joints, and the cells involved in this localization are 
still unknown. Nonetheless, in the context of the current accepted paradigm of RA evolution, 
the mucosal origin, macrophage activation and enhanced citrullination could contribute to 
disease pathogenesis and compartmentalization through multiple pathways. In the pre-clinical 
phase, environmental triggers such as cigarette smoke and microbial infections activate 
macrophages and other PAD-producing cells at the mucosal sites leading to extensive 
citrullination of intracellular and extracellular antigens. In the presence of defective tolerance 
and permissive genetic background, these citrullinated antigens are effectively presented 
leading to breach of tolerance and ACPA production [29, 30]. As the disease evolves, affinity 
maturation and epitope spreading promote humoral (ACPA) localization to the synovial 
tissues; meanwhile, inflammation-induced upregulation of homing receptors and addressins 
(e.g., α4β1/VCAM-1) on the mucosal immune cells and the synovium, respectively, mediates 
infiltration of the synovium with mononuclear cells [31, 32]. With further disease 
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progression, activated synovial tissue macrophages contribute to the local display of 
citrullinated intracellular and extracellular antigens during METosis and PAD release, 
respectively, thus promoting the final transition of systemic autoimmunity to the articular 
sites.
Activated  macrophages can make up to 30–40% of the cellular content of the RA synovium 
[33], where several mechanisms can promote their activation and PAD-dependent 
citrullination. These mechanisms include (1) engagement of macrophage TLRs with 
microbial TLR ligands [34] including EBV that has been localized in RA synovia [35] and 
reported to trigger TLR activation of macrophages [36]; (2) Macrophage activation and 
complement fixation by ACPA immune complexes’ binding FcgRs [37]; (3) Macrophages 
apoptosis [38] and bacterial-induced cytolysis [39] during which PADs are activated and 
released leading to presentation of intracellular and extracellular proteins [40].
 While peripheral tissues like the mucosal surfaces  have been widely studied as major sites of 
PAD production and antigen citrullination in RA [30], the CIA mouse model in this study 
challenges a role of the skin as a site of initial antigen entry in PAD4 expression and antigen 
citrullination. Interestingly, mycobacterium tuberculosis used in our antigen preparations with 
complete Freund’s adjuvant has been reported to express arginine deiminase [41]  which 
catabolizes free arginine into citrulline [42], however, to date, peptidyl arginine deiminases 
are only expressed in vertebrates with the only exception of Porphyromonas gingivalis [43] 
that citrullinates human fibrinogen and α-enolase [44]. 
In contrast to the skin, our data strongly supports an important role of resident lymphoid 
tissue macrophages in PAD4 expression, autoantigen citrullination and ACPA production. 
While, expression of PADs in SF and monocyte-derived macrophages has been reported and 
induction of antigen citrullination by macrophage activation using ionomycin has been 
studied [40], here we show that resident lymphoid tissue macrophages express and release 
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PAD4 in response to the more inflammation-related TLR4 ligand LPS, and that freshly 
aspirated SF macrophages and synovial organ cultures from RA patients spontaneously 
release PAD without further activation. The released enzyme was active and citrullinated 
arginine-containing peptides and native fibrinogen in vitro which implies that a similar role 
could be performed by macrophages in vivo leading to citrullination of extracellular antigens. 
Our in-situ tissue analysis indicated that CD68+ve macrophages were largely co-distributed 
with PAD4 and peptidyl citrulline in the RA synovium, as calculated by Mander’s correlation 
coefficient. However, due to the presence of PAD4 in the extracellular space where it cannot 
localize with the intracellular signal of CD68 and the expression of PAD4 by vessel-like 
structures in the synovium, the distribution was not completely overlapping. In fact, it was 
noticeable that, in the RA synovium, PAD4 has a branching serpentine labelling pattern, 
suggestive of vascular association, distinctive from the CD68 distribution. Although 
endothelial expression of PAD4 has been previously described [45], a smooth muscle cell or 
other perivascular source cannot be excluded. Specifically, we selected CD68 as a pan-
macrophage marker in order to explore PAD4 expression in all subsets of lymphoid tissue 
macrophages since other classic macrophage markers are lacking in certain subsets e.g. F4/80 
in the subcapsular sinus macrophages, and CD11b in tangible body macrophages [46].
ELSs develop in the target tissues of rheumatic autoimmune diseases including the 
rheumatoid synovium [5, 8, 9, 27]. We have previously shown that B cells differentiated 
within synovial ELS in the RA joints frequently target deiminated proteins [17], and that fully 
functional ELSs with B cell proliferation, AID expression and ongoing CSR, produce human 
IgG ACPA in active GCs [7]. While the source of citrullinated antigens driving these local 
tissue reactions is still to be fully elucidated, our results show that CD68 macrophage express 
PAD4 and colocalize with peptidyl citrulline in the inflamed RA synovia and thus could be a 
major contributor to the local generation of citrullinated antigens which induces and maintains 

27
synovial ACPA production. Although transport of citrullinated antigens from peripheral 
tissues cannot be excluded, several reports support that autoantigen citrullination is locally 
induced in the RA synovium. For example, citrullination of circulating extracellular antigens 
like fibrinogen and IgG has been reported to be dependent on local PAD expression [47]. 
Furthermore, in vitro treatment of RA synovial membranes with glucocorticoids reduced 
citrullinated proteins and PAD expression simultaneously [48]. Moreover, intracellular 
citrullinated proteins colocalize with PAD2 and correlate with local ACPA production in RA 
joints [49]. 
It is important to point out that whereas macrophages could contribute to the local generation 
of citrullinated antigens in RA SF and membranes, they are not the sole drivers of this 
process, and neutrophils can also release PADs which citrullinate extracellular antigens and 
provide citrullinated histones during NETosis [17, 50-52]. That said, macrophages uniquely 
mediate other functions beyond PAD expression and antigen citrullination; and it is the 
synergistic outcome of these functions that lend macrophages critical importance in anti-CCP 
production.
First, macrophages are professional APCs and we have shown their association with T cells in 
CIA SLOs and synovial ELSs. Remarkably, studies in mice have demonstrated that 
macrophages are the most important APC involved in processing and presentation of bovine 
collagen type II to T cells [53]. It was argued that the size and fibrillar nature of collagen type 
II influences antigen uptake and processing, and thus macrophages are the only type of APC 
able to present this antigen [54]. We reason that this might be also the case with other high 
molecular weight arthritogenic antigens including fibrinogen and extracellular matrix 
proteins. In addition, macrophages and T cells reciprocally activate each other in RA synovia. 
Macrophages TNF activated T cells, and T cell IFN enhances antigen presentation by 
macrophages [55-57].  With their capacity to citrullinate and present antigens to T cells, 
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macrophages could, thus, be a critical factor in breach of tolerance and autoimmunity in early 
arthritis. Importantly, presentation of citrullinated antigens on appropriate MHC is essential 
for the development of anti-CCP antibodies . Actually, citrullination per se is inflammation-
dependent and not RA specific [58], and in the absence of antigens that undergo citrullination 
and peptide presentation, as in pristane-induced arthritis, severe inflammatory arthritis 
develops without generation of  anti-CCP Abs [59].
The critical role of citrulline-specific T cells in anti CCP production is supported by the 
results of our in-vitro GCRs which produced anti CCP IgG only in the presence of T cells. 
Although, we have previously shown that extensive crosslinking of BCRs by FDC-retained 
antigens may induce robust T cell independent IgM responses [24, 25], however, here we 
show that ACPA IgG production is T-cell dependent. We have also shown that FDC+ ELSs 
invariably expressed AID and I-C circular transcripts indicating ongoing CSR in the 
rheumatoid synovium [7] supporting the role of ELSs in local production of this pathogenic Ig 
isotype. Indeed, it is the class-switched ACPA IgG isotype that is significantly associated 
with the pre-clinical phase of RA [60] and with RA radiographic progression [61, 62]. It is 
plausible that the T cell help provided in the autoreactive GCs induced by citrullinated 
proteins and peptides is antigen specific. Antigen specificity of TFH cells in the GCs has been 
substantiated in immunized mice, where it has been reported that  B cell – T cell contact 
during cognate recognition greatly amplifies the effective concentration of secreted cytokines 
across the immunological synapse [63], and that IL-4-producing T cells were found 
conjugated to GC B cells expressing high levels of AID, with evidence of somatic 
hypermutation [64]. In addition, prolonged contact between pMHCII-specific effector TFH 
cells and antigen-primed pMHCII+ B cells at the T-B border in the pre-GC phase is a 
prerequisite for subsequent entry of effector TFH cells into the GC reaction [65].

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Second, macrophages substantially contribute to ectopic lymphoid neogenesis where local 
autoAbs are generated. As lymphoid tissue inducers, the interaction between M1 
macrophages and vascular smooth muscle cells has been proposed to contribute to the 
formation of ELSs in athrosclerosis in TNF/LT-dependent way [66-68]. In addition, as reports 
indicate that (1) FDCs emerge from perivascular precursors [69], (2) macrophages are major 
producers of TNF in active RA [70, 71], and (3) that TNF blockade kills macrophages and 
disrupts FDC reticula in RA synovia [72-74], it is highly plausible that macrophages 
contribute to FDC development in ELSs, thus, initiating sites of B cell recruitment, antigen-
driven activation and auto-Ab production. Such contribution of macrophages to lymphoid 
neogenesis may explain the strong association of CD68 with the cellular components of ELS 
as shown by the analysis of RNA Seq data in our results. 
Mobilization of intracellular citrullinated histones, a major target of ACPA Abs, to the 
extracellular space is mandatory for BCR-mediated B cell activation, plasma cell differentiation 
and Ab production. We have reported NETosis as a potential mechanism mediating this process 
[17] , which has been recently linked to PAD4 expression and histone hypercitrullination [75]. 
Thus, we reason that a similar association exists for METosis. Indeed, here we show that LPS 
activation of macrophages (a cell lineage abundant in RA synovium) induces METosis 
contributing to citrullinated histones-driven autoimmunity. 
The mechanisms of METosis in health and disease are unfolding [76, 77]. We anticipate that 
METosis contribution to citrullination and ACPA production extends beyond mobilization of 
intracellular citrullinated antigens to the extracellular space. For example, as a consequence of 
loss of the cell membrane, METosis leads to the release of PADs and intracellular Ca+2 from 
activated macrophages which provide optimum environment for extracellular antigen 
citrullination. Remarkably, macrophages in RA synovial membranes and fluids are 
chronically activated by several inflammatory stimuli which partly explains the extensive 

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METotic figures seen in freshly aspirated SF macrophages as well as resistance to further 
stimulation by LPS in vitro. 
In conclusion, through comparable mechanisms of PAD release, extracellular antigen 
citrullination, and METosis [working model is schematically described in figure 7], our study 
shows the importance of macrophages in protein citrullination and ACPA production in  
SLOs and ELS contributing to systemic autoimmunity and articular localization of RA. 
Reducing citrullinated antigens, through selective targeting of macrophage PAD, may lead to 
the development of a novel therapeutic approach to induce long-term disease-free remission 
in RA. 
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Figure Legends
Figure 1: Expression of PAD4 in the secondary lymphoid tissues of CIA mice. Serum anti-
CCP Ab levels (A) and arthritis scores (B) of CIA mice. WB of PAD4 in the draining LNs and 
skin at the site of antigen challenge (C) as well as spleens (D) from 3 different CIA mice. 
Recombinant PAD4 and GAPDH were used as positive and negative controls respectively.  
Confocal imaging of PAD4 (i, blue), CD11c (ii, green), and CD68 (iii, red) in CIA mice spleens 
(E) and draining LNs (F) sections are shown in three separate channels. The overlay of PAD4 
and CD68 (iv), PAD4 and CD11c (v) and PAD4, CD68, and CD11c (vi) are shown. Scale bar 
200 um. (G) Colocalization of PAD4 (blue) with medullary macrophages (CD68, red) in CIA 
LNs. Higher magnification is shown in the middle panel and the intracellular localization of 
PAD4 is shown in the lower panel. Scale bar 30 um. (H) Distribution of PAD4 (blue) in CIA 
LN cortex. The LN capsule is marked with *, the GCs are labelled with GL7 (green, GC B 
cells) and CR1/2 (red, FDCs) and marked with a white arrow; and the paracortex is indicated by 
**. Scale bar 100 um. (I) Colocalization of PAD4 (blue) with CD68 (red) TBMs in the GCs 
(green, GL7, GCBs). Single channels and overlays are shown. Scale bar 100 um. (J) High 
magnification of a TBM showing colocalization of CD68 (red), PAD4 (blue), and engulfed 
apoptotic GCB cell fragments (green). Scale bar 10 um. (K) WB of PAD4 in CD11b-purified 
macrophage lysates from the draining LNs and spleens of 3 different CIA mice. Controls as in 
C and D.
Figure 2: Distribution of citrullinated proteins / peptides in the draining LNs and spleens of 
CIA mice; and the impact of macrophage depletion on lymphoid tissue citrulline and serum 
ACPA levels. (A-i) IHC and confocal tile scanning of CD68 (red) and peptidyl citrulline (green) 
in a mid-saggital section of the draining LNs of CIA mice show cortical retention of peptidyl 
citrulline (white rectangle] and colocalization with CD68 in the medulla (dashed rectangle). 
Single colour channels are shown to the left of the merged image. High magnification imaging of 
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the LN medulla (A-ii) and cortex (A-iii) showing peptidyl citrulline distribution in relation to 
CD68. Scale bar 100 um. (B-i) IHC and confocal tile scanning of CD68 (red) and peptidyl 
citrulline (green) in CIA mice spleens showing peptidyl citrulline retention in follicular (white 
pulp – white ellipse) and extrafollicular (red pulp – dashed ellipse) regions. (B-ii) High 
magnification imaging shows colocalization of peptidyl citrulline with CD68 (**) and 
intrafollicular retention of peptidyl citrulline. Single color channels are shown to the left of the 
merged image. Scale bar 100 um. (C, D) DBA/1 mice were injected with F4/80 mAb i.p. for three 
successive days before injection of collagen II (CII) in CFA. Macrophage subsets were assessed 
by flow cytometry (dot plots in c) at day 0 (just before induction of CIA) and 3 weeks later and 
data is expressed as % of macrophages in total splenocytes (in D) (E) Citrulline content of the 
CIA spleens 3 and 4 weeks after CII/CFA administration with or without F4/80 treatment. 
Citrulline was measured by sandwich ELISA and expressed as ODs at 450 after normalization to 
the protein concentrations for each sample. (F) ELISA measurement of serum anti-CCP levels 
[weeks 1-4] in CIA mice with and without macrophage depletion using anti F4/80 mAb. 
Signifincance was calculated using unpaired 2-tailed student T test and the p values between 
F4/80 treated and untreated CIA (CII/CFA)  mice are shown at the corresponding time point.  
Figure 3: Activated murine macrophages release PAD4 and display extracellular trap 
formation (METosis). (A) Assessment of PAD activity in the culture supernatants of in vitro 
activated macrophages using different concentrations of LPS (10-1000 ng/ml). Conversion of 
peptidyl arginine into peptidyl citrulline by released PAD is detected in ELISA by specific mAb.  
PMA is included as a positive control. Signifincance was calculated using unpaired 2-tailed 
student T test and the p values between the unstimulated control and the treated conditions are 
shown. (B) Confocal imagining of purified splenic macrophages after 4 hr stimulation with 
10ng/ml LPS. DNA is shown blue and DNA-associated citrullinated histones are shown in red. 
Unstimulated and PMA activated cells were used as negative and positive controls respectively. 
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High magnification of macrophage extracellular traps (METs) is shown on the right and 
citrullinated histones are indicated by white arrows. Scale bar = 50 m except in the image with 
white arrows showing citrullinated histones, scale bar = 0.5 mm (C) Confocal imagining of in 
vitro generated TBM after 4 hr stimulation with 10ng/ml LPS. TBMs are labelled red (CD68), 
DNA (blue), and apoptotic B cells are labelled green with CSFE. Single channels, dual and triple 
colour overlays are shown and a high magnification of the released apoptotic B cell fragments in 
the METs are shown on the right (white arrow). Scale bare = 50 m. 
Figure 4: Induction of ACPA in in vitro GCRs and interaction of T and B cells with 
peptidyl citrulline-associated macrophages and FDCs in the draining LNs of CIA mice. 
(A) Low (i) and high (ii, iii) magnification confocal imaging of CD3+ T cells (blue), CD68+ 
macrophages (red) and peptidyl citrulline (green) in the draining LNs of CIA mice. The 
interaction between macrophages and T cells in the paracortex is represented in (iii, dashed 
ellipse). Scale bar 100 um. (B) Peptidyl citrulline (green) in the B cell follicles is retained on 
CD21+ FDCs (red). Single colour channels are shown above the overlay. Scale bar 100 um (C) 
ICOS+ Tfh cells (red) are seen in the light zone of the GC in association with peptidyl citrulline-
retaining FDC reticula (blue) and PNA+ activated GC B cells (green)in the draining LNs of CIA 
mice. Scale bar 100 um (D) GC in the DNLs of CIA mice labelled with anti-peptidyl citrulline 
(blue), the activated GC B cell marker (PNA, green), and the plasma cell marker Blimp 1 (red, 
white arrow). Scale bar 100 um. (E) Purified FDCs with dendritic morphology are shown with 
Nomarski optics (i), and the nuclei are stained blue (ii). Citrullinated fibrinogen (red) is shown on 
FDCs with rhodamine-conjugated anti fibrinogen Ab (iii) and few contaminating lymphocytes are 
shown adjacent to the white arrows. Scale bare = 10 m. (F) Reconstitution of GCRs in vitro 
using citrullinated-fibrinogen IC-loaded FDCs with B and T cells from the spleens of CIA mice. 
The in vitro cultures are shown at day 1 (i) and day 5 (ii) after setup of the co-culture. (G) ACPA 
production in in vitro GCRs at day 5. Scale bar = 100 m. Data expressed as the mean + SEM.  
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Signifincance was calculated using 2-tailed unpaired student T test and the p value between 
FDC+T cell costimulated conditions and FDC-only co-culture controls is shown.
Figure 5: Expression of PAD4 and distribution of peptidyl citrulline in RA synovial tissues 
with ELSs. Low (i) and high (ii) magnification of IHC staining of RA synovial tissue 
macrophages (CD68, red) and PAD4 (green) in (A); and the distribution of peptidyl citrulline 
(blue) in relation to macrophages (CD68, green) in (B). (C) ELS stained for CD20+ B cells 
(blue), macrophages (CD68, red) and PAD4 (green). Low and high magnifications are shown in 
(i) and (ii) respectively. (D, E, and F) low (i) and high (ii) magnification of adjacent RA 
synovial cryo-sections with ELSs (*). Colocalization of peptidyl citrulline (blue) with CD68 
macrophages (red) and CD3+ T cells (green) is shown in D-i with representative interaction 
between CD3+ T cells and CD68+ macrophages/peptidyl citrulline shown in D-ii (dashed 
ellipse).  (E-i) Peptidyl citrulline (blue) retention on CD21+ FDCs (green) indicated by white 
arrow in E-ii (corresponding to ELS with yellow*). (F-i) colocalization of peptidyl citrulline 
(blue), CD20+ B cells (red) and CD3+ T cells (green). (F-ii) High magnification of the ELS with 
yellow*. (G-i) Expression of the plasma cell-associated Blimp-1 transcription factor (red) in 
ELS of RA synovia with CD20+ B cells shown in green. (G-ii) High magnification of G-i with 
a white arrow pointing at Blimp-1. (H) Correlation of CD68 gene expression in RA synovia with 
various pathotypes and the histological scoring of T cells/CD3, B cells/CD20 and plasma 
cells/CD138.  (I) Correlation of CD68 gene expression with CD3E (T cell-CD3e gene), CR2 
(FDC-CD21 gene), MS4A1 (B cell-CD20 gene), and PRDM1 (plasma cell-Blimp-1 gene) in RA 
synovia. Correlation (r) and adjusted p values are shown with the corresponding plot. (J) In situ 
colocalization of CD68 (green), peptidyl citrulline (blue), and PAD4 (red) using Mander’s 
correlation coefficient. Representative overlays of the probes are shown in i, ii, and iii; and the 
corresponding correlation plots are shown in iv, v, and vi respectively. In vii, a triple overlay of 
CD68, PAD4, and peptidyl citrulline shows intracellular [white box] extracellular [dashed white 
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box] and vessel-associated PAD4 [double white box] in the RA synovium. Scale bar 50 m 
except Gii = 10 um   
Figure 6: METosis and release of PAD from RA synovial fluid (SF) macrophages and 
organ cultures. (A-i) Enriched RA SF macrophages were cultured in vitro for 24 hrs in the 
presence or absence of different LPS concentrations (10-1000 ng/ml); and tonsillar macrophages 
were used as a control. PAD activity in the culture supernatants were assessed by ELISA and the 
ODs at 450 are shown. (A-ii) light microscopy of freshly aspirated RA SF macrophages show 
METosis (extruded network of nuclear material is marked with *). (A-iii, iv) 
Immunofluorescence of freshly aspirated RA SF showing METosis (networks of DNA, blue in iii 
and iv), release of citrullinated histones (red, white arrow in  iii), and release of PAD4 (red, green 
arrow in vi). (A-v) Anti citrullinated histone H3 shows no staining in SF macrophages from 
psoriatic arthritis patients (negative control)  scale bar = 50 m. (B-i) PAD activity in the culture 
supernatants and lysates of RA synovial membrane cultures. (B-ii) Schematic representation of 
the setup of synovial organ cultures, and an image of the actual cultures  (B-iii) showing synovial 
tissue (S) on filter devices (F) cultured in medium (M). In A-i and B-i, signifincance was 
calculated using 2-tailed unpaired student T test and the p values between control tonsillar 
macrophages and  synovial fluid macrophages and synovial organ culture supernatants are 
indicated.
Figure 7: Schematic representation of the proposed role lymphoid tissue macrophages in 
citrullination and ACPA production in autoimmune arthritis. Macrophage activation (1) 
by TLRLs, ICs, and proinflammatory cytokines induces PAD4 release which citrullinates 
native extracellular proteins (2), releases citrullinated intracellular antigens (e.g. citrullinated 
histones) by METosis (3); and presentation of citrullinated peptides to T cells (4). B cell 
activation by citrullinated antigens retained on FDCs (5) in the presence of T cell help (6) 
induces plasma cell differentiation and ACPA production. 

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Table 1: List of Abs used in this study
Primary Abs: 
Clone Reactivity Target Host Format Vendor Cat No. 
N418 Mouse CD11c Ar. Hamster AF 488 Biolegend 117311
FA-11 Mouse CD68 Rat AF 594 Biolegend 137020
145-2C11 Mouse CD3e Rat Biotin Biolegend 100304
GL7 Mouse B and T cell activation antigen Rat FITC [IgM] BD Biosciences 553666
7E9 Mouse CD21/CD35 (CR1/CR2) Rat PE Biolegend 123410
Polyclonal Mouse / Human Histone H3 (citrulline R2,R8,R17) Rabbit Un-conjugated Abcam ab5103
L26 Human CD20 (cytoplasmic) Mouse Un-conjugated Dako M0755
F7.2.38 Human CD3 Mouse Un-conjugated Dako M7254
KP1 Human CD68 Mouse Un-conjugated Dako M0814
MI15 Human CD138 Mouse Un-conjugated Dako M7228
1F8 Human CD21 Mouse Un-conjugated Dako M0784
7E.17G9 Mouse ICOS Rat PE Biolegend 117405
Polyclonal Human CD3 Rabbit Un-conjugated Dako A0452
F95 Mouse / Human Peptidyl Citrulline Mouse Un-conjugated [IgM] EMD Millipore MABN328
Polyclonal Mouse / Human Blimp-1 (N-20) Goat PE Santa Cruz Biotechnology Sc-13203
B-Ly1 Human CD20 Mouse RPE Dako R7013
Polyclonal Mouse / Human PAD4 Rabbit Un-conjugated Abcam ab50247
2ry Abs and other stains: 
Polyclonal Rabbit IgG (H+L) Donkey F(ab')2 - AF 594 Jackson Immuno Research 711-586-152
Polyclonal Rabbit IgG (H+L) Donkey F(ab')2 - AF 647 Jackson Immuno Research 711-606-152
Polyclonal Rabbit IgG (H+L) Donkey F(ab')2 - AF 488 Jackson Immuno Research 711-546-152
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Polyclonal Mouse IgM u chain Donkey F(ab')2 - AF 488 Jackson Immuno Research 715-546-020
Polyclonal Mouse IgM u chain Goat Dylight 649 Jackson Immuno Research 115-495-075
Polyclonal Mouse IgM u chain Donkey AF 594 Jackson Immuno Research 715-585-140
Polyclonal Mouse IgG (H+L) Donkey F(ab')2 - AF 647 Jackson Immuno Research 715-606-150
Polyclonal Mouse IgG (H+L) Donkey F(ab')2 - AF 488 Jackson Immuno Research 715-456-150
Polyclonal Mouse IgG (H+L) Donkey F(ab')2 - Rhodamine RX Jackson Immuno Research 715-296-151
Peanut agglutinin 
(PNA) Mouse Galactose on GCB Plant Lectin Fluorescein Vector Laboratories FL1071
- - DNA - 647 Nuclear Probe ThermoFisher Scientific R37106
- - Biotin - Streptavidin AF 647 Life Technologies S32357
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